Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir ; volume:20 ; number:1 ; day:13 ; month:3 ; year:2023 ; pages:1-11 ; date:12.2023
AIDS research and therapy ; 20, Heft 1 (13.3.2023), 1-11, 12.2023
- Creator
-
Mulindwa, Frank
Castelnuovo, Barbara
Brusselaers, Nele
Bollinger, Robert
Rhein, Joshua
Edrisa, Mutebi
Buzibye, Allan
Amutuhaire, Willington
Yendewa, George
Nabaggala, Sarah
Odongpiny, Eva Laker Agnes
Kiguba, Ronald
Nakawooza, Aisha
Dujanga, Simon
Nabwana, Martin
Schwarz, Jean-Marc
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12981-023-00510-6
- URN
-
urn:nbn:de:101:1-2408070919030.961454761132
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mulindwa, Frank
- Castelnuovo, Barbara
- Brusselaers, Nele
- Bollinger, Robert
- Rhein, Joshua
- Edrisa, Mutebi
- Buzibye, Allan
- Amutuhaire, Willington
- Yendewa, George
- Nabaggala, Sarah
- Odongpiny, Eva Laker Agnes
- Kiguba, Ronald
- Nakawooza, Aisha
- Dujanga, Simon
- Nabwana, Martin
- Schwarz, Jean-Marc
- SpringerLink (Online service)
Other Objects (12)
Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
Creation of a long-acting nanoformulated dolutegravir
Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy
Modifying dolutegravir to PrEPare for long life
Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment
Dolutegravir (HIV-Infektion) : Addendum zum Auftrag A17-11
Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
Creation of a long-acting nanoformulated dolutegravir
Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy
Modifying dolutegravir to PrEPare for long life
Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment
Dolutegravir (HIV-Infektion) : Addendum zum Auftrag A17-11
Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
Creation of a long-acting nanoformulated dolutegravir
Incidence and determinants of adverse events in individuals with HIV commencing Dolutegravir-based antiretroviral therapy in mainland Tanzania
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy
Modifying dolutegravir to PrEPare for long life
Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment